<DOC>
	<DOCNO>NCT00492765</DOCNO>
	<brief_summary>This study find benefit add Simvastatin Interferon-beta-1a patient Multiple Sclerosis .</brief_summary>
	<brief_title>Simvastatin Add-on Treatment Interferon-beta-1a Treatment Relapsing-Remitting Multiple Sclerosis</brief_title>
	<detailed_description>This multi-centre , double blind , placebo control , randomise , parallel group , phase 4 study . Following three month treatment Interferon beta 1a ( Avonex ) patient randomise treatment simvastatin placebo add-on interferon -beta-1a ( Avonex√í ) . Patients start treatment 40 mg peroral simvastatin daily identically appear placebo one month . Hereafter , patient escalate dosage 80 mg daily . The patient examine clinically baseline , 3 , 4 , 6 , 9 , 12 15 month . Patients attend visit 5 ( 15 month ) last patient attend visit ask attend additional visit ( visit 6+ ) last patient attend visit 5 . Clinical examination perform , applicable patient , 3 month interval end study . This maximum two year , i.e . eight additional visit . Laboratory assessment perform screen 3 , 4 , 6 , 9 , 12 15 month baseline , applicable patient additionally 3 month interval end study . MRI perform ( T1-weighted T2-weighted ) randomisation ( 3 month baseline ) 12 month hereafter .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Is age 18 55 year ( include ) Relapsingremitting MS accord Poser criterion ( CDMS LSDMS ) 22 definite MS accord McDonald criterion 23 Disability equivalent EDSS 5.5 less 21 Clinical activity define least one report documented relapse within last year Patient must prepare consider able follow protocol whole study period attend plan visit , even treatment withdrawn Any condition might give rise similar symptom MS Immunomodulatory immunosuppressive treatment MS prior inclusion study ( prior pulse steroid treatment relapse allow ) Treatment glucocorticoid ACTH later one month prior inclusion study , i.e . screen visit Onset relapse within one month prior inclusion study , i.e . screen visit History major depression Alcohol drug dependency Cardiac insufficiency , cardiomyopathy , significant cardiac dysrhythmia , unstable advanced ischemic heart disease ( NYHA III IV ) Significant hypertension ( BP &gt; 180/110 mmHg ) Renal insufficiency define serum creatinine &gt; 1.5 time upper normal reference limit Total plasma cholesterol &lt; 3.5 mmol/L Any medical illness require treatment systemic corticosteroid Any systemic disease influence patient 's safety compliance , evaluation disability Women pregnant , breastfeed possibility pregnancy study . To avoid pregnancy , woman postmenopausal , surgically sterile , sexually inactive practice reliable contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Combination therapy</keyword>
	<keyword>Simvastatin</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Interferon-beta-1a</keyword>
</DOC>